- Total grants
- Total funders
- Total recipients
- Earliest award date
- 23 Jan 2006
- Latest award date
- 30 Sep 2017
- Total GBP grants
- Total GBP awarded
- Largest GBP award
- Smallest GBP award
- Total Non-GBP grants
Imagine if we could watch multiple molecules in living cells as they move and interact. This dream may seem years away, but it is now realistic to achieve real-time dynamic super-resolution imaging of multiple tagged proteins in three dimensions (3D) in cells and in tissues. This will allow biologists to discover large-scale patterns involving diverse structures including transport vesicles, ribosomes, and chromatin domains, all previously inaccessible because they lie in the gap between the resolution of electron (1- 2 nm) and light microscopy (200-300 nm). The "big picture" of cellular organization/information processing would emerge, with advances in understanding cell function in health and disease. While we can now do this in 2D, 3D imaging is needed to follow objects as they move out of the plane. Achieving 3D imaging is a major challenge and will require two orders of magnitude more information per cellular volume, and novel algorithms to classify, analyze, and visualize patterns from massive datasets. We propose specific innovations (Table 1) that, should allow us to achieve this over the next five years, given our team’s proven track record of success.
Collectively: 100% Unstoppable 30 Sep 2016
COP21 is just weeks away. Governments are edging towards an agreement but at the moment it’s expected to be 33-50% short of what’s needed to deliver a 2C world. Governments can be emboldened to close this gap if they hear a strong voice from business and citizens that we believe change is necessary, possible and will lead to better outcomes for nations, communities, the economy and the planet. The UNFCCC is asking organisations to think of it as the ‘Road Through Paris’ not the ‘Road to Paris’: COP21 must be a stepping stone to even more action and momentum in 2016. There is emerging momentum behind the idea of ‘100%’ clean energy future, in particular led through local/state government - 100% New York, London, California. We believe we have a unique opportunity to ‘move the dial’ before, during and after COP21 by using the Collectively Platform to: Build a sense of unstoppable momentum towards a renewable energy future by driving and publically joining up the commitments of big corporates and their brands, and organisations and influencers from popular culture, sport and cities. Engage millennials globally in the role they can play to make a renewable energy future happen today. Positively influence the COP21 negotiations by showing the corporate and citizen/consumer commitment to change. Campaign concept: #Weareunstoppable. Are you with us? Change is happening all around us, a clean energy future is on its way, its progress unstoppable. The time is now raise your voice / make the change. We need leaders to match, not get in the way of this ambition. Example tweet: Collectively we’re making London air safe to breathe. Are you with us @NewYork? #weareunstoppable #go100percent. Phase 1: #Weareunstoppable (5 Nov- 15 Dec) A community building phase which invites in as big and broad an audience as possible and warms them up for a higher barrier action later. Editorial builds excitement and social capital around energy by: Linking it to millennial ‘passion points’ including health. Highlight the difference between "dirty" and "clean" energy Grow our "unstoppable" Collectively community through sign ups Showcase 100% – what is happening alongside COP21? Why should we add our voice to the climate negotiations regardless of the official outcome?
Established in 2004 at EMBL-EBI, PRIDE is the world-leading proteomics data repository and, since 2011, is leading the ProteomeXchange Consortium, standardising public proteomics data submission and dissemination worldwide. The success of PRIDE and ProteomeXchange, has largely driven the proteomics community to widely embracing open data policies. To continue serving and shaping this increasingly prominent field, we primarily request support for the further development of PRIDE as a repository, to enable an efficient handling of proteomics ‘big data’ such as the increasingly large datasets generated from clinical studies. A key component is the development of a submission Application Programming Interface that can be integrated in third-party software. Second, PRIDE will become a Hub for proteomics data, by establishing robust data dissemination pipelines to key resources (UniProt, Ensembl/Ensembl Genomes, Expression Atlas), enabling proteomics data reuse by all biological researchers. We will build novel, open quality control pipelines to ensure that only high-quality data is propagated. Third, also to facilitate data reuse, we will develop and make available open, reproducible proteomics data analysis pipelines tailored for multi-omics approaches used e.g. in personalised medicine. These pipelines will be connected to PRIDE, bringing cutting-edge analysis tools closer to the data, as datasets become larger.
Imperium 15 May 2017
Imperium is a factual comedy drama, wrapped up in a prescient satire of our very near future. It’s about surveillance, technology, control, big business, and small communities. And it’s a love story. A simple love story. About an LSD addicted snobbish woman falling for a charming working-class loser after he gives her a bin to piss in, before stalking him using the best surveillance equipment in the world, accidentally ruining his life and then trying to make amends.
Health and economic benefits of water-sensitive revitalisation in informal urban settlements 06 Oct 2016
Urbanisation is a major demographic trend globally. Informal settlements account for much urban growth, exacerbating the inextricably linked challenges of sanitation, water provision, and public health. The conventional ‘big pipes’ solution to these challenges has changed little in 150 years, comes at major financial, environmental, and social costs, and frequently overlooks informal settlements. We have pioneered an alternative, water-sensitive approach that integrates sustainable design with the management of the water-cycle, benefiting human health and urban ecosystems. This decentralised, climate-change sensitive approach provides financial flexibility for multistage developments and adaptability to future technologies. It promises a solution to the water services challenges of informal settlements, yet has only been demonstrated in developed world settings. We will examine whether the water-sensitive approach can be applied to revitalise developing-world informal settlements to improve environmental and public health outcomes. Our evidence-based assessment of its efficacy across 24 settlements, poorly served by water infrastructure in Makassar and Suva, will deliver the first public health and environmental data on the benefits and risks of water-sensitive approaches. Our scientific, economic and implementation findings will provide the basis for profound changes to infrastructure policies, investments, loan strategies, and their sustainability across the Asia-Pacific and the developing world.
MetaboFlow - the development of standardised workflows for processing metabolomics data to aid reproducible data sharing and big data initiatives 16 Jun 2016
The processing and analysis of mass spectrometry and nuclear magnetic resonance spectroscopy data in metabolomics is largely performed on an individual basis following local laboratory methodologies. Metabolomics lacks reproducible computational workflows based on internationally accepted standard operating procedures and this is impacting on the field in terms of reproducibility of studies and subsequent sharing of data. Furthermore, with improvements in reproducibility in analytical equipment, individual laboratories are acquiring larger, more complex datasets, which are a significant challenge to process. We propose to build, test and deliver the cloud-based Galaxy workflow, MetaboFlow, which will have computational capacity to process datasets with 1000s of samples and simultaneously capture all metadata associated with the users’ data processing workflow to allow rigorous reproducibility. We will formulate the workflow using several popular processing, feature extraction and compound identification tools and provide functionality to readily use on-line databases including our international repository, MetaboLights. The tools will be selected based on our current survey of the international metabolomics community. This proposal is a re-submission following consultation with the Trust. Specifically we have developed and implemented a plan to capture the communities’ needs, and have made significant cost savings by integrating our work with other initiatives using Galaxy.
Visualizing Citizen Voice in a Moment of 'Big Data'
Recruitment and Career Development ISSF has funded start-up packages (equipment, PhD studentships, laboratory consumables and relocation costs) for the recruitment of outstanding biomedical researchers. These new recruits work across cell and molecular biology, bacteriology, immunology, parasitology and drug discovery. The ISSF has also been used to provide bridging support for researchers experiencing short-term funding gaps. This flexible and reactive support has enabled PhD students and investigators to generate data for key publications and successful grant/fellowship applications. Enhancement of Research Infrastructure The ISSF has supported our strategy to have innovative core facilities in key research areas and to develop computational and informatics resources that underpin our WT funded research. Software developers have been appointed to develop computational and informatics resources to support the outstanding mass spectrometry-based proteomics facility in the School of Life Sciences. Novel ways of managing, visualising and analysing ‘big data’ in the field of quantitative proteomics have been developed, in addition to a customised Laboratory Information Management System (LIMS). Translational Research A flexible Translation Medical Research Fund (TMRF) was used to link the strongest basic and clinical research across the University of Dundee (2011-2014). Funding was awarded on a competitive basis and 25 different projects have been supported including; Pump-priming projects, Strategic projects that benefitted several groups across the University and increase overall institutional competitiveness in translational research; and translational medicine (non-clinical) PhD projects. Public Engagement The ISSF supports community engagement activities targeted at the next generation of scientists to enhance a culture of curiosity, confidence and engagement with science with our communities. A key aim is to increase awareness of Life Sciences Research in schools in areas of social deprivation to promote widening of access to opportunities in science. ISSF funds support the appointment of a School Outreach Organiser (this post greatly increases the quality and scope of our work and supports public engagement activities of our WT funded researchers); school projects; city and rural Science Festivals, the Dundee Women in Science Festival; projects to translate science into public art; an interactive display at the Dundee Science Centre; a Life Sciences career paths booklet and website (through interviews, time-lines and photographs); Open Doors Days; Magnificent Microbes and Marvellous Microbes activities; Café Science; Bright Club science comedy; public talks and debates. The impact of activities is assessed by questionnaires and reflective feedback discussions with stakeholders. We plan a quarterly public survey in Dundee to capture audience knowledge of the Life Science Research and Wellcome Trust activities. This will give us a measure of whether public engagement activities are reaching the community.
Carnival of the Brain. 08 Oct 2014
Edinburgh International Science Festival plan to develop and deliver a brand new immersive workshop, Carnival of the Brain, to be staged in our flagship family venue, City Art Centre, in April 2015. Aimed at engaging children, families, and independent adults, this workshop is a celebratory exploration of the brain and the senses, created in partnership with the British Psychological Society. Carnival of the Brain will transform a section of City Art Centre into a journey through the brain, themed around a retro carnival setting. Audiences will step through a visually exciting entrance to the gateway of the mind, and follow carnival-style signposts that direct them to drop-in workshop activities that use traditional carnival activities to explore areas of the brain: e.g. the Frontal Lobe, Occipital Lobe, Peripheral Nervous System, Brainstem and the Big Brain Top. These will run alongside other activities, such as wall-based illusions and communicator-led challenges and puzzles. Set in a traditional fairground environment, this workshop will have a distinctive and playful atmosphere that appeals to audiences of all ages. We will use creative props, lighting and set-dressing to stage an immersive environment that provides a fresh approach to hands-on science. This workshop will be developed in close consultation with our scientific partners, to ensure that real-world applications of science and the role of psychology are incorporated into each activity, providing audi ences with a greater understanding of how their brains work, and the importance of research in this field.
A proof of concept Phase IIb efficacy trial to evaluate the protective efficacy of a booster MVA85A vaccination administered to BCG primed infants in the Western Cape. 20 Dec 2011
Summary not available
MVA85A Tuberculosis Vaccine Prime and Selective Delayed BCG Boost in Infants of HIV Infected Mothers. 16 May 2011
Bacille Calmette Guerin (BCG) vaccine protects against childhood disseminated tuberculosis (TB) and meningitis, but efficacy against pulmonary TB is inconsistent. Administration of live attenuated BCG to known HIV infected infants is contraindicated by the World Health Organization (WHO), due to risk of disseminated BCG disease. BCG disease causes considerable morbidity, may be fatal, and may manifest as immune reconstitution inflammatory syndrome (IRIS) after starting antiretroviral treatment (ART). Developing countries, which lack capacity for integration of early HIV testing with infant vaccination schedules, have not implemented the WHO guidelines. Babies of HIV infected mothers, who constituted 29% of all babies born in South Africa in 2009, would benefit from a new TB vaccine regimen that delays BCG until after HIV infection has been excluded. We have shown in humans that delaying BCG vaccination until 10 weeks of age results in more optimal T cell immune responses. Animal studies suggest that the prime and boost sequence of BCG and new TB vaccines (heterologous prime and boost) is not critical for development of optimal immunity. One new vaccine, MVA85A, a non-replicating Vaccinia virus expressing M.tuberculosis antigen 85A, has been tested as a TB vaccine boost among infants, children and adults. We will build on a long-standing relationship with the vaccine developers, Oxford University and Emergent Biosolutions, to test whether MVA85A can be given as the priming TB vaccine at birth. Exceptional research capacity and immunology laboratory infrastructure has been established to conduct quality-assured TB vaccine trials at our trial sites near Cape Town, South Africa. This randomised controlled trial will test safety (local, regional, and systemic adverse events) and immunogenicity (serial measurements of CD4/CD8 T cell intracellular cytokine production, cytotoxic and proliferative potential) of MVA85A prime vaccination compared to placebo, in 340 newborns of HIV infected mothers, followed at 8 weeks by selective BCG boost, given only to infants confirmed HIV uninfected by PCR. The safety benefit gained by withholding BCG vaccination from HIV infected infants is the rationale for testing MVA85A prime among newborn infants of HIV infected mothers. The precedent safety and immunogenicity data from this strategically important trial will establish the equipoise to fast-track efficacy trials of this novel TB vaccine regimen among all infants, regardless of maternal HIV infection. The findings, which are of global health importance for vaccine safety, and TB control, among HIV exposed children, may lead to key improvements in the routine infant vaccination schedule.
Characterising control of mycobacterial growth in patients with TB disease and M. tuberculosis infection. 18 Feb 2014
TB can be viewed as a continuous spectrum extending from sterilising immunity, quiescent M. tuberculosis (M.tb) infection, and active disease. Identifying phenotypic subgroups within this spectrum is challenging and the tools we use are currently imperfect. An understanding of protective immunity against TB disease is lacking, as are predictors of risk of disease progression, biomarkers of responses to therapy and correlates of vaccine-induced protection. Mycobacterial growth inhibition assays offer a functional in-vitro evaluation of an individual's capacity to control mycobacterial growth. Preliminary data indicate that individuals with active disease exhibit greater control of mycobacterial growth that those with latent M.tb infection. My hypothesis is that this is related to the bacillary load experienced by the individual, akin to the spectrum of responses observed in another mycobacterial disease (leprosy). Humoral immune responses may contribute to the spectrum of M.tb infect ion (as in leprosy). I propose to study three populations of HIV-negative adults: a group with latent M.tb infection, a group with active pulmonary disease; a group of healthy, BCG-vaccinated and -na ve, controls. Associations between clinical phenotype, functional assay and B and T cell-associated immune signatures (by flow cytometry and gene expression) may help identify correlates of protective immunity and valuable host biomarkers.
Transforming tissue repair: ‘out-of-the-bag’ elastic meshes that accelerate wound repair 23 Jan 2014
Professor Anthony Weiss, University of Sydney, and collaborator Dr Rob Daniels of Elastagen, are developing a novel product to repair full thickness skin wounds arising from injury, surgery or disease. The product being developed is a mesh produced from elastin, a protein naturally present in the skin as fibres which are responsible for the skin's elastic properties.Elastin also plays an important role in the regeneration of skin tissue following injury; however, as we age our bodies lose the ability to produce sufficient elastin to support this repair process. Through this Wellcome Trust sponsored research and development program the elastin mesh product is being refined to optimise its physical and biological properties and its safety and efficacy will be evaluated in preclinical models.
At-Bristol's experience in exhibition development, learning programmes and online interactivity enables us to produce multi-stranded projects that tackleinterdisciplinary issues and challenges in the 21st century. Moving Bodies will bring together and build on the learning, experience and exhibits developed from previous At-Bristol exhibitions and programmes. Moving Bodies is a 150m2 facilitated, outdoor exhibition that is flexible, energetic and highly interactive. Moving Bodies will tour throughout the UK during 2012. Moving Bodies includes: o Branded inflatable dome - a flexible environment for the exhibition that canbe configuration to suit the venue requirements o Exhibits - 5 portable interactive exhibits, including 10m running track o Satellite link- provides independent link to the web uploading personalised data from the exhibition o Stage area - science theatre demonstration, live lab equipment, Moving Bodies own BIG screen o Branding/marketing tools - entrance mall, barcode collection points, featherflags and graphic barriers. o Generator - giving independence and freedom to travel the exhibition to any venue o Customised Moving Bodies branded transport Through the Moving Bodies exhibition we aim to: o Highlight body energy/power and link to technique as an overarching theme o Create content that explore the human body and its physiology through the exhibits and facilitated demonstrations o Develop a Live Lab experience to further the visitors engagement with the exhibition o Provide personalised experiences that are captured within the exhibition anduploaded to the Explore More website www.movingbodies.org.uk o Highlight the passion, dedication and determination individuals show in their chosen field or profession. Moving Bodies will tour to at least 12 major large scale events throughout the12 regions of the UK. We aim to place the exhibition in the reach of over 1.5 million people and we anticipate 500,000 individuals would receive an engagement experience with the Moving Bodies exhibition. We will operate the tour from May to September 2012. At Bristol has an excellent track record of delivering high quality interactive exhibition that are both permanent and touring. Our project team has a wealth of experience in managing touring exhibitions throughout the UK and overseas including a 6 month travelling exhibition around South Africa, travelling exhibitions to other institutions, exhibit hire and sales around the world. We also have experience of taking interactive exhibitions and showsto large scale events and festivals. Having completed our latest Wellcome funded exhibition All About Us earlier this month, we are ideally placed to build on and continue the challenging work of inspiring our visitors about the beauty and complexity of the human body.
We Cannot Unsee. 01 Oct 2014
As the British Film Institute stages a major retrospective of Science Fiction film, We Cannot Unsee asks: can science-fiction get closer to the lived, subjective experience of psychological disorders than written, codified scientific definitions, like those contained in DSM-IV? We Cannot Unsee is initiated and overseen by British Film Institute, in collaboration with no.w.here, University of the Arts, London and researchers based at Kings College London. The project takes its title from the d escription of someone suffering from Palinopsia, a condition whereby after images appear to linger - a prime example of a condition that begs to be explored via film, not words. We Cannot Unsee will result in a number of short, experimental films that explore the potential of science-fiction imagery and narratives to communicate the ways people experience a range of symptoms associated with psychiatric and brain disorders. With the support of no.w.here, a visual research and development labo ratory for artists, emerging artists (studying at or recently graduated from UAL colleges) will create films in collaboration with Vaughan Bell, Lidia Yaguez-Hervas, Zerrin Atakan from the Institute of Psychiatry Kings College and Pat Walsh from the Centre of Medical Law and Ethics. The project will also seek input from those who experience these symptoms first hand. By utilizing film - a visual form which offers alternative non-linear, non-verbal impressionistic ways to convey experience - We C annot Unsee aims to deepen our understanding of symptoms associated with pathopsychologies, and reassign agency to those who experience them.
The conference 'The Total Archive' and associated special issue of the journal LIMN deals with schemes for universal knowledge, from mass bio-sample collection and global demography to representations of totalities in film, fiction and visual art. The conference seeks to interrogate the practices of Big Data and the identity politics of sciences with grand explanatory claims, for example modern genomics. The conference takes place on March 19/20, 2015, at the Centre for Research in the Arts, Hum anities and Social Sciences (CRASSH), University of Cambridge. In addition to the urgent need to contextualise Big Data (see: http://www.mpiwg-berlin.mpg.de/en/research/projects/DeptII_Aronova_Oertzen_Sepkoski_Historicizing), the conference is timely because of the increasing use of large data-sets and aspirations to totality in the humanities themselves. For example CRASSH's own 'Visual Representations of the Third Plague Pandemic' is one such project represented at the conference. Theme s of mass data collection are also important outside the academy, and so the conference will feature a public lecture (by the literary theorist Katherine Hayles), and essays will be published in the popular open access journal LIMN (www.limn.it), which has agreed in principle to run a special issue on the topic.
Understanding variability in systems pharmacology with application to drug target identification 31 Oct 2012
There is currently a big gap between understanding the molecular mechanisms ofbiological networks, identifying drug targets and predicting clinical outcomes of drug treatments in a heterogeneous population of patients. The goal of this project is to narrow this gap by developing a framework that combines mechanistic systems modelling, drug pharmacokinetics and patient variability in a unified fashion. This framework will enable us to make progress in understanding healthy and diseased network physiology, guide us to select optimal drug interventions andquantitatively predict the success of drug therapies on variable patient subpopulations. Specifically, I will develop a quantitative systems pharmacology (QSP) model of a nerve growth factor (NGF) signalling pathway using clinical and molecular data. I will extend the existing model to capture variability in the biological pathway as well as variability between and within individual patients. The model will be used to identify robust drugtargets and to guide aspects of quantitative drug discovery and development for treating paindisorders.
Insuring healthcare in a digital world. 09 Apr 2015
Huge claims are being made about the impact of digital technologies on healthcare provision. As digital health, Big Data and the Internet of Things converge with insurance systems, healthcare is to become more democratic, more personalized; individual health data will be captured on devices and shared directly with public and private health providers and insurers; competition to find ways of measuring, using, valuing and monetising data will intensify. A systematic assessment of these claims is urgently required. Our project will explore the practices and ethics of digital recording and economic valuation of individual health data. Private insurance schemes already reward healthier behaviour. The NHS has embraced the use of apps to change behavior, and is running pilot schemes to integrate data from wearable devices into Patient Heath Records. But who decides what constitutes healthier behaviour, and by which digital health measures? Can citizen-consumer-patients opt out or have oversi ght of all the uses to which their data might be put? Should individuals be held financially responsible for their own health? Our pilot study will focus initially on the extent of digital-financial health convergence in the UK using digital research methods and in-depth interviews with emerging key actors in the sector.
Drawing on Life. 16 Apr 2008
The project consists of a series of collaborations between leading UVL scientists, artists - including a strong team from the Slade School of Fine Art - and UCL Museums & Collections, leading to a day of public events showcasing drawing for the Big Draw national launch on 27th September. Supported by the Campaign for Drawing, the project will produce a range of innovative interactive visual experiences for the public and for students around the theme of seeing and understanding the human body for inside and out, presenting new biomedical imaging techniques alongside artists responses to them.